GRACELL BIOTECHNOLOGIES-ADR (GRCL) Fundamental Analysis & Valuation

NASDAQ:GRCL • US38406L1035

Current stock price

10.25 USD
+0.01 (+0.05%)
At close:
10.25 USD
0 (0%)
After Hours:

This GRCL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. GRCL Profitability Analysis

1.1 Basic Checks

  • In the past year GRCL has reported negative net income.
  • GRCL had a negative operating cash flow in the past year.
GRCL Yearly Net Income VS EBIT VS OCF VS FCFGRCL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -200M -400M -600M

1.2 Ratios

  • With a Return On Assets value of -43.64%, GRCL perfoms like the industry average, outperforming 57.55% of the companies in the same industry.
  • GRCL's Return On Equity of -52.90% is fine compared to the rest of the industry. GRCL outperforms 64.77% of its industry peers.
Industry RankSector Rank
ROA -43.64%
ROE -52.9%
ROIC N/A
ROA(3y)-29.05%
ROA(5y)-37.01%
ROE(3y)-34.16%
ROE(5y)-644.48%
ROIC(3y)N/A
ROIC(5y)N/A
GRCL Yearly ROA, ROE, ROICGRCL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for GRCL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRCL Yearly Profit, Operating, Gross MarginsGRCL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -20K -40K -60K -80K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. GRCL Health Analysis

2.1 Basic Checks

  • GRCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • GRCL has about the same amout of shares outstanding than it did 1 year ago.
  • GRCL has a worse debt/assets ratio than last year.
GRCL Yearly Shares OutstandingGRCL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 20M 40M 60M 80M
GRCL Yearly Total Debt VS Total AssetsGRCL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 500M 1B 1.5B 2B

2.2 Solvency

  • GRCL has an Altman-Z score of 15.19. This indicates that GRCL is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of GRCL (15.19) is better than 88.25% of its industry peers.
  • GRCL has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • GRCL has a Debt to Equity ratio of 0.12. This is in the lower half of the industry: GRCL underperforms 67.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 15.19
ROIC/WACCN/A
WACC9.48%
GRCL Yearly LT Debt VS Equity VS FCFGRCL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 500M -500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 6.44 indicates that GRCL has no problem at all paying its short term obligations.
  • GRCL's Current ratio of 6.44 is fine compared to the rest of the industry. GRCL outperforms 61.74% of its industry peers.
  • GRCL has a Quick Ratio of 6.44. This indicates that GRCL is financially healthy and has no problem in meeting its short term obligations.
  • GRCL's Quick ratio of 6.44 is fine compared to the rest of the industry. GRCL outperforms 62.58% of its industry peers.
Industry RankSector Rank
Current Ratio 6.44
Quick Ratio 6.44
GRCL Yearly Current Assets VS Current LiabilitesGRCL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. GRCL Growth Analysis

3.1 Past

  • The earnings per share for GRCL have decreased by -4.00% in the last year.
  • The Revenue for GRCL has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, GRCL will show a very negative growth in Earnings Per Share. The EPS will decrease by -18.88% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.78%
EPS Next 2Y25.47%
EPS Next 3Y3.89%
EPS Next 5Y-18.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRCL Yearly Revenue VS EstimatesGRCL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2026 2027 2028 2029 2030 1B 2B 3B 4B
GRCL Yearly EPS VS EstimatesGRCL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. GRCL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GRCL. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRCL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRCL Price Earnings VS Forward Price EarningsGRCL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRCL Per share dataGRCL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.47%
EPS Next 3Y3.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GRCL Dividend Analysis

5.1 Amount

  • No dividends for GRCL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

GRCL Fundamentals: All Metrics, Ratios and Statistics

GRACELL BIOTECHNOLOGIES-ADR

NASDAQ:GRCL (2/21/2024, 8:00:01 PM)

After market: 10.25 0 (0%)

10.25

+0.01 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-11
Inst Owners0.05%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap989.87M
Revenue(TTM)N/A
Net Income(TTM)-601.28M
Analysts78.67
Price Target10.76 (4.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.8%
Min EPS beat(2)13.13%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)-34.87%
Min EPS beat(4)-136.32%
Max EPS beat(4)26.47%
EPS beat(8)3
Avg EPS beat(8)-77.59%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.31%
PT rev (3m)-9.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)22.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.27
P/tB 6.27
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0
BVpS1.64
TBVpS1.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.64%
ROE -52.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.05%
ROA(5y)-37.01%
ROE(3y)-34.16%
ROE(5y)-644.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.93%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.44
Quick Ratio 6.44
Altman-Z 15.19
F-Score1
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)192.19%
Cap/Depr(5y)411.73%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y29.78%
EPS Next 2Y25.47%
EPS Next 3Y3.89%
EPS Next 5Y-18.88%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.22%
EBIT Next 3Y-7.21%
EBIT Next 5YN/A
FCF growth 1Y-46.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.48%
OCF growth 3YN/A
OCF growth 5YN/A

GRACELL BIOTECHNOLOGIES-ADR / GRCL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GRACELL BIOTECHNOLOGIES-ADR (GRCL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to GRCL.


What is the valuation status for GRCL stock?

ChartMill assigns a valuation rating of 0 / 10 to GRACELL BIOTECHNOLOGIES-ADR (GRCL). This can be considered as Overvalued.


What is the profitability of GRCL stock?

GRACELL BIOTECHNOLOGIES-ADR (GRCL) has a profitability rating of 1 / 10.